Loading...
XLONEDEN
Market cap26mUSD
Dec 27, Last price  
3.95GBP
1D
0.00%
1Q
-1.25%
Jan 2017
-65.60%
IPO
-79.71%
Name

Eden Research PLC

Chart & Performance

D1W1MN
XLON:EDEN chart
P/E
—
P/S
660.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.11%
Rev. gr., 5y
2.85%
Revenues
3m
+74.70%
193,000172,00091,00043,59080,22399,855883,312391,9581,877,1872,774,2721,825,5011,368,9881,228,5801,827,1713,192,027
Net income
-6m
L+190.28%
-1,727,000-3,251,000-3,284,000-2,317,134-1,587,909-2,969,468-1,157,103-1,831,092-639,093-334,951-1,144,703-2,270,347-2,788,973-2,237,262-6,494,249
CFO
-2m
L+148.20%
-432,000-1,751,000-2,628,000-1,621,505-1,245,977-930,295-104,861-805,789230,041-701,678-1,013,299-1,015,309-1,618,558-683,095-1,695,411
Earnings
May 05, 2025

Profile

Eden Research plc offers sustainable solutions for crop protection, animal health, and consumer products in the United Kingdom and rest of Europe. The company provides crop protection products for foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatment applications. It also offers animal health products, such as companion animal, bio-control, parasite treatments, and insect spray products. In addition, the company provides human health products comprising head-lice treatment products, fragrances, deodorants, wound-care products, food flavorings, odor neutralizers, and active ingredient supply/delivery products. The company was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.
URL
http://www.edenresearch.com/
IPO date
May 11, 2012
Employees
19
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,192
74.70%
1,827
48.72%
1,229
-10.26%
Cost of revenue
4,424
4,678
4,652
Unusual Expense (Income)
NOPBT
(1,232)
(2,851)
(3,423)
NOPBT Margin
Operating Taxes
(428)
(324)
(618)
Tax Rate
NOPAT
(804)
(2,527)
(2,805)
Net income
(6,494)
190.28%
(2,237)
-19.78%
(2,789)
22.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,058
BB yield
-37.43%
Debt
Debt current
143
140
100
Long-term debt
317
432
597
Deferred revenue
Other long-term liabilities
88
Net debt
(7,251)
(1,754)
(3,494)
Cash flow
Cash from operating activities
(1,695)
(683)
(1,619)
CAPEX
(102)
(1,054)
(1,726)
Cash from investing activities
(1,719)
(1,054)
(1,726)
Cash from financing activities
8,902
(150)
(90)
FCF
(1,684)
(1,854)
(2,204)
Balance
Cash
7,413
1,994
3,829
Long term investments
297
330
362
Excess cash
7,551
2,233
4,130
Stockholders' equity
7,132
(28,566)
(26,479)
Invested Capital
6,643
39,611
39,749
ROIC
ROCE
EV
Common stock shares outstanding
420,921
380,549
380,340
Price
0.06
21.05%
0.05
 
Market cap
24,203
33.89%
18,076
 
EV
16,979
16,347
EBITDA
(607)
(2,164)
(2,833)
EV/EBITDA
Interest
17
22
32
Interest/NOPBT